Our Pricing

Wegovy 1.7mg: Your Prescription Weight Loss Solution

Seeking wegovy 1.7mg uk prescription online? At Cured Pharmacy, you'll access genuine UK-licensed Wegovy 1.7mg pens from £79.00, with transparent upfront pricing and free clinical consultation by UK-registered prescribers. The 1.7mg dose represents a key maintenance stage in your semaglutide weight loss journey, typically reached after careful dose escalation.

Understanding Wegovy 1.7mg in Your Dosing Schedule

Wegovy 1.7mg represents the fourth dose level in the structured semaglutide escalation protocol licensed by the MHRA. This dose follows the 0.25mg, 0.5mg, and 1mg stages, each maintained for four weeks to optimise gastrointestinal tolerance whilst your body adapts to semaglutide's appetite-regulating effects [1].

Clinical experience shows that patients typically reach the 1.7mg dose during weeks 13-16 of treatment, subject to prescriber assessment of tolerability and response. At this stage, many patients report significant appetite reduction and steady weight loss progress, though individual responses vary considerably [1].

The gradual dose escalation to 1.7mg isn't arbitrary—it's designed to minimise gastrointestinal side effects like nausea and vomiting whilst maximising treatment adherence. In the STEP clinical trials, this methodical approach helped 89% of participants complete the full dose escalation to the maximum 2.4mg maintenance dose [2].

How Wegovy 1.7mg Works for Weight Loss

Semaglutide, the active pharmaceutical ingredient in Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics a natural hormone your gut produces after eating. At the 1.7mg dose, semaglutide creates sustained activation of GLP-1 receptors in your brain's appetite centres, pancreas, and digestive system [1].

This multi-system approach produces three key effects: reduced hunger signals from your hypothalamus, delayed gastric emptying that prolongs satiety after meals, and improved glucose regulation. Together, these mechanisms help you consume fewer calories without the constant hunger that derails traditional calorie-restriction diets [2].

In the landmark STEP-1 trial, participants using semaglutide achieved an average 14.9% body weight reduction over 68 weeks—substantially higher than the 2.4% seen with placebo. Importantly, weight loss continued progressively through the dose escalation phases, with significant reductions already evident at the 1.7mg level before reaching the maximum 2.4mg maintenance dose [2].

What to Expect at the 1.7mg Dose Level

Most patients at the 1.7mg stage report noticeable appetite suppression, with reduced portion sizes and decreased food cravings between meals. You may find yourself naturally eating smaller portions and feeling satisfied sooner during meals. Some patients experience mild nausea during the first week at this dose, though this typically resolves as your body adjusts. Your UK prescriber will monitor your progress and side effects before determining whether to advance to the final 2.4mg maintenance dose after four weeks at 1.7mg, subject to clinical assessment of your individual response and tolerability.

Wegovy 1.7mg Price UK and What's Included

At Cured Pharmacy, Wegovy treatment starts from £79.00, with transparent pricing displayed before you begin your free online consultation. This competitive UK pricing includes your medication, clinical assessment by a UK-registered prescriber, and discreet delivery to your chosen address.

Each Wegovy pen contains four doses, meaning one 1.7mg pen provides your monthly supply when you're injecting once weekly at this dose level. Your prescription will specify the quantity needed based on your treatment duration, and our clinical team ensures you receive the correct pen strength for your current stage in the dose escalation protocol.

Unlike some UK pharmacies that add hidden consultation fees or delivery charges at checkout, Cured Pharmacy maintains transparent upfront pricing. What you see is what you pay—no surprise fees, no subscription traps, just genuine UK-licensed Wegovy delivered discreetly to your door after prescriber approval.

Wegovy 1.7mg vs Other Weight Loss Injections

When comparing weight loss injections available through UK pharmacies, understanding the differences between semaglutide-based treatments and newer alternatives helps you make informed decisions with your prescriber. Wegovy contains semaglutide, a single GLP-1 receptor agonist, whilst newer medications like Mounjaro use tirzepatide, which activates both GLP-1 and GIP receptors for potentially greater weight loss [3].

Saxenda, another UK-licensed weight loss injection, contains liraglutide—an earlier GLP-1 medication requiring daily injections rather than Wegovy's once-weekly dosing. Clinical trials suggest semaglutide produces greater average weight loss than liraglutide, though individual responses vary, and some patients may respond better to one medication over another [4].

Your UK prescriber will consider your medical history, previous treatment responses, BMI, comorbidities, and personal preferences when recommending the most appropriate weight loss medication. The 1.7mg Wegovy dose may be ideal for patients who've tolerated earlier escalation stages well and are progressing toward the maximum maintenance dose, subject to clinical assessment.

Choosing Between Wegovy Dose Strengths

You cannot simply choose the 1.7mg dose without medical assessment—UK prescribing guidelines require systematic dose escalation starting at 0.25mg. Your prescriber determines when you're ready to advance from 1.7mg to the final 2.4mg maintenance dose based on your weight loss progress, side effect tolerability, and overall clinical response. Some patients may remain at 1.7mg if this dose achieves their weight loss goals with minimal side effects, whilst others continue to 2.4mg for maximum efficacy. This individualised approach optimises outcomes whilst maintaining safety, and your UK clinical team will guide you through each stage of your treatment journey.

Wegovy 1.7mg Side Effects and Safety Considerations

The most commonly reported side effects at the 1.7mg dose level include nausea, diarrhoea, constipation, vomiting, and abdominal discomfort. In the STEP trials, gastrointestinal side effects were generally mild to moderate and decreased over time as patients adapted to each dose level [2].

Approximately 5-10% of patients experience persistent nausea at the 1.7mg dose, though this often improves within 1-2 weeks. Eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated can help manage these symptoms. If side effects become intolerable, your prescriber may recommend remaining at the 1mg dose longer or implementing other management strategies [2].

Serious side effects are rare but require immediate medical attention. These include severe abdominal pain (potential pancreatitis), persistent vomiting leading to dehydration, changes in vision, rapid heartbeat, or signs of thyroid tumours such as a lump in your neck. Wegovy carries a boxed warning regarding thyroid C-cell tumours observed in rodent studies, though human relevance remains unclear. Your prescriber will assess your personal and family medical history before prescribing [1][2].

Wegovy is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It should be used cautiously in patients with diabetic retinopathy, renal impairment, or history of pancreatitis. All prescription decisions require thorough clinical assessment by a UK-registered prescriber who will evaluate your individual risk-benefit profile.

How to Order Wegovy 1.7mg Online from Cured Pharmacy

Ordering Wegovy 1.7mg through Cured Pharmacy begins with a free online consultation that takes under three minutes to complete. You'll answer medical history questions about your weight, previous weight loss attempts, current medications, and relevant health conditions. This information allows our UK-registered prescribers to assess whether Wegovy is clinically appropriate for you.

If approved, your prescription is issued electronically and sent directly to our dispensary. Our pharmacist team, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), verifies every prescription and dispenses genuine UK-licensed Wegovy from MHRA-approved wholesalers. Your medication is then packaged discreetly—nothing on the exterior indicates the contents—and dispatched for delivery to your specified address.

You'll receive tracking information once your order ships, and our clinical team remains available by phone ((+44) 116 4646009) if you have questions about your treatment. Follow-up consultations ensure your dose escalation proceeds safely, and you can reorder your next month's supply through your online account when needed. All ongoing prescriptions require periodic clinical review to monitor your progress and adjust treatment as necessary, subject to prescriber approval.

What Happens After Your First 1.7mg Month

After completing four weeks at the 1.7mg dose level, your prescriber will assess whether you're ready to advance to the final 2.4mg maintenance dose or whether remaining at 1.7mg is more appropriate for your individual circumstances. This decision considers your weight loss progress, side effect tolerability, and overall treatment response. Some patients achieve their target weight loss at 1.7mg and may not require the higher dose, whilst others benefit from advancing to 2.4mg for maximum efficacy. Your UK clinical team will guide this decision through ongoing consultation and monitoring, ensuring your treatment plan remains optimised for your personal health goals and medical profile.

Scientific References

1. Novo Nordisk. (2023). Wegovy 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
4. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., & Wilding, J. P. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on multiple factors including diet, exercise, and adherence to treatment.